華海藥業(600521.SH):鹽酸美金剛片獲得藥品註冊證書
格隆匯8月31日丨華海藥業(600521.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的鹽酸美金剛片的《藥品註冊證書》。
鹽酸美金剛片主要用於治療中重度至重度阿爾茨海默型痴呆。鹽酸美金剛片最早於2002年在歐盟被批准上市,持證商為H.LundbeckA/S。全球主要生產廠商有H.LundbeckA/S、Allergan、第一三共株式會社等,國內生產廠商主要有珠海聯邦制藥、石藥集團歐意藥業、揚子江藥業、白雲山製藥等。
據統計,2020年4月至2021年3月,鹽酸美金剛製劑產品全球市場銷售額約9.89億美元(數據來源於Newport數據庫);2020年鹽酸美金剛片國內銷售額約人民幣6.2億元(數據來源於米內網)。
截止目前,公司在鹽酸美金剛片研發項目上已投入研發費用約人民幣331.82萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.